Immunology Case Reports

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Immunology Case Reports (2023) Volume 6, Issue 4

Secretome-based acellular therapy in degenerative and immunological disorders

Satyaraj Maggidi*

Department of Medicine, Madurai Kamaraj University, India

*Corresponding Author:
Satyaraj Maggidi
Department of Medicine
Madurai Kamaraj University

Received:30-July-2023, Manuscript No. AAICR-23-109020; Editor assigned:04-Aug-2023, PreQC No. AAICR-23-109020(PQ); Reviewed:18-Aug-2023, QC No. AAICR-23-109020; Revised:24-Aug-2023, Manuscript No. AAICR-23-109020(R); Published:31-Aug-2023, DOI:10.35841/aaicr-6.4.165

Citation: Maggidi S. Secretome-based acellular therapy in degenerative and immunological disorders. Immunol Case Rep. 2023;6(4):165

Visit for more related articles at Immunology Case Reports


In recent years, regenerative medicine has witnessed groundbreaking advancements in the treatment of degenerative and immunological disorders. One promising approach gaining traction is secretome-based acellular therapy. Rather than using live cells, this innovative strategy focuses on harnessing the therapeutic potential of secretomes – the complex mix of bioactive molecules, growth factors, cytokines, and extracellular vesicles released by cells. This article explores the application of secretome-based acellular therapy in degenerative and immunological disorders and its potential to revolutionize the field of regenerative medicine [1].

The secretome refers to the myriad of bioactive molecules and signaling factors that cells release into their surrounding microenvironment. These secreted factors play essential roles in cell communication, tissue repair, and immune modulation. In the context of regenerative medicine, scientists have increasingly recognized that the secretome can drive beneficial effects independent of the cells themselves. Acellular therapy, on the other hand, represents a departure from traditional cell-based therapies. Instead of transplanting living cells into a patient, acellular therapies utilize the biologically active factors present in the secretome to exert their therapeutic effects. This approach presents several advantages, such as reduced immune rejection, minimized risks of tumor formation, and easier storage and transport [2].

Secretome-based acellular therapy in degenerative disorders

Neurodegenerative Diseases: Neurological disorders like Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS) pose significant challenges to conventional therapeutic approaches. However, studies have shown that the secretome of certain stem cells and progenitor cells can promote neuroprotection, neurogenesis, and neural network repair. These secretomes have demonstrated the ability to modulate inflammation, reduce oxidative stress, and stimulate cell survival in the central nervous system. By harnessing these properties, secretome-based acellular therapy offers hope for slowing down or even reversing neurodegenerative processes. Osteoarthritis and Cartilage Repair: Joint degeneration, particularly in osteoarthritis, is a prevalent degenerative disorder affecting millions worldwide. Secretome-based acellular therapies have shown promise in promoting chondrogenesis, reducing inflammation, and enhancing cartilage repair. These therapies have the potential to provide a regenerative solution for those suffering from chronic joint pain and functional impairment [3].

Secretome-based acellular therapy in degenerative disorders

Cardiovascular Disorders: Heart diseases such as myocardial infarction and heart failure can lead to irreversible damage to cardiac tissue. Secretome-based acellular therapy offers a novel approach to stimulate angiogenesis, promote cardiac cell survival, and reduce fibrosis. The regenerative potential of the secretome may aid in restoring cardiac function, potentially revolutionizing the treatment of cardiovascular disorders [4].

Secretome-based acellular therapy in immunological disorders

Autoimmune Diseases: In autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and type 1 diabetes, the immune system mistakenly attacks the body's own tissues. Secretome-based acellular therapy presents an intriguing avenue for immunomodulation, where the bioactive factors in the secretome can regulate immune responses, promote tolerance, and inhibit inflammation. By modifying the immune system's behavior, this therapy could alleviate symptoms and halt disease progression. Graft-versus-Host Disease (GvHD): GvHD is a severe complication that can occur after stem cell or bone marrow transplantation. In this condition, donor immune cells attack the recipient's tissues, leading to significant morbidity and mortality. Secretome-based acellular therapy may offer a more targeted and safer approach to prevent or treat GvHD by modulating immune responses while avoiding the potential risks associated with live cell transplantation [5].


The advent of secretome-based acellular therapy marks a significant milestone in the field of regenerative medicine. This innovative approach capitalizes on the therapeutic potential of the secretome, offering a safer and more targeted alternative to conventional cell-based therapies. As ongoing research and clinical trials continue to shed light on the intricate mechanisms of the secretome and its applications, we can look forward to a new era in the treatment of degenerative and immunological disorders. By harnessing the natural healing capabilities of the secretome, patients may one day experience improved outcomes, enhanced quality of life, and a brighter future in the face of these challenging medical conditions.


  1. Rehman AU, Olsson PO, Akhtar A, et al. Systematic molecular analysis of the human secretome and membrane proteome in gastrointestinal adenocarcinomas. J Cell Mol Med. 2022;26(12):3329-42.
  2. Indexed at, Google Scholar, Cross Ref

  3. Kim J, Koo BK, Knoblich JA. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol. 2020;21(10):571-84.
  4. Indexed at, Google Scholar,Cross Ref

  5. Liu Z, Yang S, Li X, et al. Local transplantation of GMSC-derived exosomes to promote vascularized diabetic wound healing by regulating the Wnt/β-catenin pathways. Nanoscale Advances. 2023;5(3):916-26.
  6. Indexed at, Google Scholar, Cross Ref

  7. Xu H, Zhu Y, Hsiao AW, et al. Bioactive glass-elicited stem cell-derived extracellular vesicles regulate M2 macrophage polarization and angiogenesis to improve tendon regeneration and functional recovery. Biomaterials. 2023;294:121998.
  8. Indexed at, Google Scholar, Cross Ref

  9. Zheng M, Kanneganti TD. Newly identified function of caspase-6 in ZBP1-mediated innate immune responses, NLRP3 inflammasome activation, PANoptosis, and host defense. J Cell Immunol. 2020;2(6):341.
  10. Indexed at, Google Scholar, Cross Ref

Get the App